Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype

Purpose Myocardial infarction results in physiological derangements that lead to structural and functional alterations to the myocardium. In addition, oxidative stress potentiates cardiac remodeling and drives disease progression. Unfortunately, treatment with antioxidants in clinical trials have fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular drugs and therapy 2017-02, Vol.31 (1), p.29-38
Hauptverfasser: Rogers, Russell G., Otis, Jeffrey S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue 1
container_start_page 29
container_title Cardiovascular drugs and therapy
container_volume 31
creator Rogers, Russell G.
Otis, Jeffrey S.
description Purpose Myocardial infarction results in physiological derangements that lead to structural and functional alterations to the myocardium. In addition, oxidative stress potentiates cardiac remodeling and drives disease progression. Unfortunately, treatment with antioxidants in clinical trials have failed to show any therapeutic benefits despite the positive results reported in animal studies, which warrants further investigation into their mechanism(s) of action. Accordingly, the aim of this study was to elucidate a previously unknown mechanism of action for the antioxidant, resveratrol, in the treatment of the ischemic heart. Methods Male Sprague-Dawley rats underwent four weeks of chronic myocardial ischemia with or without daily resveratrol treatment (10 mg/kg/day). The expression and signaling of Krüppel-like factor 15 (KLF15) were determined by immunoblot and qPCR analyses, respectively. Results Chronic myocardial ischemia reduced the protein expression of KLF15. In parallel, mRNA transcripts of KLF15 gene targets actively involved in cardiac remodeling were robustly increased in untreated hearts. Importantly, daily treatment with resveratrol stimulated KLF15 expression, which was associated with attenuated gene expression and an improved cardiac phenotype. Additionally, we describe a novel role for KLF15 in the regulation of redox homeostasis. Conclusion Based on our current findings, it appears that resveratrol treatment induces KLF15 expression, which may, in part, explain its therapeutic efficacy to improve the cardiac phenotype following ischemic injury.
doi_str_mv 10.1007/s10557-016-6707-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881751865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4320260911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-7dc0ceb32601b3e8031517c5cc2c4a428d4a045b3013d222f68806a7a8d6a1593</originalsourceid><addsrcrecordid>eNqNkV2LEzEUhoMobl39Ad5IwBtvoufkey6XsqvFLoro9ZBmUpulM6nJzK7996bOKiIIXgWS531zDg8hzxFeI4B5UxCUMgxQM23AsOYBWaAyghku8SFZQMOBCQ76jDwp5QZqpmnsY3LGLWgpwS7I-CmU25DdmNOeXYcuujF09PL7IYdSYhpo2tL36ytUNA503AW6Kn4X-ujp9TF5l7s49TQWelFK8nP4Lo476ga66g853daL5Qlznn7chSGNx0N4Sh5t3b6EZ_fnOflydfl5-Y6tP7xdLS_WzEtQIzOdBx82gmvAjQgWBCo0XnnPvXSS2046kGojAEXHOd9qW_dyxtlOO1SNOCev5t46yLcplLHtY_Fhv3dDSFNp0Vo0Cq1W_4EqbbUUEiv68i_0Jk15qItUymghDfwsxJnyOZWSw7Y95Ni7fGwR2pO9drbXVnvtyV57mvfFffO06UP3O_FLVwX4DJT6NHwN-Y-v_9n6A6OTo0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876347065</pqid></control><display><type>article</type><title>Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rogers, Russell G. ; Otis, Jeffrey S.</creator><creatorcontrib>Rogers, Russell G. ; Otis, Jeffrey S.</creatorcontrib><description>Purpose Myocardial infarction results in physiological derangements that lead to structural and functional alterations to the myocardium. In addition, oxidative stress potentiates cardiac remodeling and drives disease progression. Unfortunately, treatment with antioxidants in clinical trials have failed to show any therapeutic benefits despite the positive results reported in animal studies, which warrants further investigation into their mechanism(s) of action. Accordingly, the aim of this study was to elucidate a previously unknown mechanism of action for the antioxidant, resveratrol, in the treatment of the ischemic heart. Methods Male Sprague-Dawley rats underwent four weeks of chronic myocardial ischemia with or without daily resveratrol treatment (10 mg/kg/day). The expression and signaling of Krüppel-like factor 15 (KLF15) were determined by immunoblot and qPCR analyses, respectively. Results Chronic myocardial ischemia reduced the protein expression of KLF15. In parallel, mRNA transcripts of KLF15 gene targets actively involved in cardiac remodeling were robustly increased in untreated hearts. Importantly, daily treatment with resveratrol stimulated KLF15 expression, which was associated with attenuated gene expression and an improved cardiac phenotype. Additionally, we describe a novel role for KLF15 in the regulation of redox homeostasis. Conclusion Based on our current findings, it appears that resveratrol treatment induces KLF15 expression, which may, in part, explain its therapeutic efficacy to improve the cardiac phenotype following ischemic injury.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-016-6707-9</identifier><identifier>PMID: 28064408</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Antioxidant Response Elements - drug effects ; Antioxidants - pharmacology ; Cardiology ; Disease Models, Animal ; Kruppel-Like Transcription Factors - genetics ; Kruppel-Like Transcription Factors - metabolism ; Male ; Medicine ; Medicine &amp; Public Health ; Myocardial Infarction - drug therapy ; Myocardial Infarction - genetics ; Myocardial Infarction - metabolism ; Myocardial Infarction - physiopathology ; Myocardium - metabolism ; Myocardium - pathology ; NF-E2-Related Factor 2 - metabolism ; Original Article ; Oxidation-Reduction ; Oxidative Stress - drug effects ; Phenotype ; Rats, Sprague-Dawley ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Stilbenes - pharmacology ; Time Factors ; Up-Regulation ; Ventricular Remodeling - drug effects</subject><ispartof>Cardiovascular drugs and therapy, 2017-02, Vol.31 (1), p.29-38</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Cardiovascular Drugs and Therapy is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-7dc0ceb32601b3e8031517c5cc2c4a428d4a045b3013d222f68806a7a8d6a1593</citedby><cites>FETCH-LOGICAL-c405t-7dc0ceb32601b3e8031517c5cc2c4a428d4a045b3013d222f68806a7a8d6a1593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10557-016-6707-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10557-016-6707-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28064408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rogers, Russell G.</creatorcontrib><creatorcontrib>Otis, Jeffrey S.</creatorcontrib><title>Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Purpose Myocardial infarction results in physiological derangements that lead to structural and functional alterations to the myocardium. In addition, oxidative stress potentiates cardiac remodeling and drives disease progression. Unfortunately, treatment with antioxidants in clinical trials have failed to show any therapeutic benefits despite the positive results reported in animal studies, which warrants further investigation into their mechanism(s) of action. Accordingly, the aim of this study was to elucidate a previously unknown mechanism of action for the antioxidant, resveratrol, in the treatment of the ischemic heart. Methods Male Sprague-Dawley rats underwent four weeks of chronic myocardial ischemia with or without daily resveratrol treatment (10 mg/kg/day). The expression and signaling of Krüppel-like factor 15 (KLF15) were determined by immunoblot and qPCR analyses, respectively. Results Chronic myocardial ischemia reduced the protein expression of KLF15. In parallel, mRNA transcripts of KLF15 gene targets actively involved in cardiac remodeling were robustly increased in untreated hearts. Importantly, daily treatment with resveratrol stimulated KLF15 expression, which was associated with attenuated gene expression and an improved cardiac phenotype. Additionally, we describe a novel role for KLF15 in the regulation of redox homeostasis. Conclusion Based on our current findings, it appears that resveratrol treatment induces KLF15 expression, which may, in part, explain its therapeutic efficacy to improve the cardiac phenotype following ischemic injury.</description><subject>Animals</subject><subject>Antioxidant Response Elements - drug effects</subject><subject>Antioxidants - pharmacology</subject><subject>Cardiology</subject><subject>Disease Models, Animal</subject><subject>Kruppel-Like Transcription Factors - genetics</subject><subject>Kruppel-Like Transcription Factors - metabolism</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - genetics</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>NF-E2-Related Factor 2 - metabolism</subject><subject>Original Article</subject><subject>Oxidation-Reduction</subject><subject>Oxidative Stress - drug effects</subject><subject>Phenotype</subject><subject>Rats, Sprague-Dawley</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Stilbenes - pharmacology</subject><subject>Time Factors</subject><subject>Up-Regulation</subject><subject>Ventricular Remodeling - drug effects</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkV2LEzEUhoMobl39Ad5IwBtvoufkey6XsqvFLoro9ZBmUpulM6nJzK7996bOKiIIXgWS531zDg8hzxFeI4B5UxCUMgxQM23AsOYBWaAyghku8SFZQMOBCQ76jDwp5QZqpmnsY3LGLWgpwS7I-CmU25DdmNOeXYcuujF09PL7IYdSYhpo2tL36ytUNA503AW6Kn4X-ujp9TF5l7s49TQWelFK8nP4Lo476ga66g853daL5Qlznn7chSGNx0N4Sh5t3b6EZ_fnOflydfl5-Y6tP7xdLS_WzEtQIzOdBx82gmvAjQgWBCo0XnnPvXSS2046kGojAEXHOd9qW_dyxtlOO1SNOCev5t46yLcplLHtY_Fhv3dDSFNp0Vo0Cq1W_4EqbbUUEiv68i_0Jk15qItUymghDfwsxJnyOZWSw7Y95Ni7fGwR2pO9drbXVnvtyV57mvfFffO06UP3O_FLVwX4DJT6NHwN-Y-v_9n6A6OTo0A</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Rogers, Russell G.</creator><creator>Otis, Jeffrey S.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope></search><sort><creationdate>20170201</creationdate><title>Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype</title><author>Rogers, Russell G. ; Otis, Jeffrey S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-7dc0ceb32601b3e8031517c5cc2c4a428d4a045b3013d222f68806a7a8d6a1593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antioxidant Response Elements - drug effects</topic><topic>Antioxidants - pharmacology</topic><topic>Cardiology</topic><topic>Disease Models, Animal</topic><topic>Kruppel-Like Transcription Factors - genetics</topic><topic>Kruppel-Like Transcription Factors - metabolism</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - genetics</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>NF-E2-Related Factor 2 - metabolism</topic><topic>Original Article</topic><topic>Oxidation-Reduction</topic><topic>Oxidative Stress - drug effects</topic><topic>Phenotype</topic><topic>Rats, Sprague-Dawley</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Stilbenes - pharmacology</topic><topic>Time Factors</topic><topic>Up-Regulation</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rogers, Russell G.</creatorcontrib><creatorcontrib>Otis, Jeffrey S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rogers, Russell G.</au><au>Otis, Jeffrey S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>31</volume><issue>1</issue><spage>29</spage><epage>38</epage><pages>29-38</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>Purpose Myocardial infarction results in physiological derangements that lead to structural and functional alterations to the myocardium. In addition, oxidative stress potentiates cardiac remodeling and drives disease progression. Unfortunately, treatment with antioxidants in clinical trials have failed to show any therapeutic benefits despite the positive results reported in animal studies, which warrants further investigation into their mechanism(s) of action. Accordingly, the aim of this study was to elucidate a previously unknown mechanism of action for the antioxidant, resveratrol, in the treatment of the ischemic heart. Methods Male Sprague-Dawley rats underwent four weeks of chronic myocardial ischemia with or without daily resveratrol treatment (10 mg/kg/day). The expression and signaling of Krüppel-like factor 15 (KLF15) were determined by immunoblot and qPCR analyses, respectively. Results Chronic myocardial ischemia reduced the protein expression of KLF15. In parallel, mRNA transcripts of KLF15 gene targets actively involved in cardiac remodeling were robustly increased in untreated hearts. Importantly, daily treatment with resveratrol stimulated KLF15 expression, which was associated with attenuated gene expression and an improved cardiac phenotype. Additionally, we describe a novel role for KLF15 in the regulation of redox homeostasis. Conclusion Based on our current findings, it appears that resveratrol treatment induces KLF15 expression, which may, in part, explain its therapeutic efficacy to improve the cardiac phenotype following ischemic injury.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28064408</pmid><doi>10.1007/s10557-016-6707-9</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-3206
ispartof Cardiovascular drugs and therapy, 2017-02, Vol.31 (1), p.29-38
issn 0920-3206
1573-7241
language eng
recordid cdi_proquest_miscellaneous_1881751865
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Animals
Antioxidant Response Elements - drug effects
Antioxidants - pharmacology
Cardiology
Disease Models, Animal
Kruppel-Like Transcription Factors - genetics
Kruppel-Like Transcription Factors - metabolism
Male
Medicine
Medicine & Public Health
Myocardial Infarction - drug therapy
Myocardial Infarction - genetics
Myocardial Infarction - metabolism
Myocardial Infarction - physiopathology
Myocardium - metabolism
Myocardium - pathology
NF-E2-Related Factor 2 - metabolism
Original Article
Oxidation-Reduction
Oxidative Stress - drug effects
Phenotype
Rats, Sprague-Dawley
RNA, Messenger - genetics
RNA, Messenger - metabolism
Stilbenes - pharmacology
Time Factors
Up-Regulation
Ventricular Remodeling - drug effects
title Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A39%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resveratrol-Mediated%20Expression%20of%20KLF15%20in%20the%20Ischemic%20Myocardium%20is%20Associated%20with%20an%20Improved%20Cardiac%20Phenotype&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Rogers,%20Russell%20G.&rft.date=2017-02-01&rft.volume=31&rft.issue=1&rft.spage=29&rft.epage=38&rft.pages=29-38&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/s10557-016-6707-9&rft_dat=%3Cproquest_cross%3E4320260911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1876347065&rft_id=info:pmid/28064408&rfr_iscdi=true